0300 B0x-seg

Serial N	y		RANSMITTAL LE						o. 10466/264
	eñal No. 9/989,293		Filing Date November 20, 2001		Examiner To be assigned			Group Art Unit 1645	
Inventor Ashkena									
Title of I	nvention	MENADDAN	E POLYPEPTIDE	CAND MICE	C A C	IDS ENCODIN	C THE SA	ME	
SECKE	TED AND TRAINS	IVIEWDRAN					O ITIL OA	in i r	
				OMMISSIONER					
Listing i	Transmitted her n computer reada	rewith is <u>a S</u> able_form; c	tatement Accordin	g to 37C.F.R. § Comply with F	1.82° equir	1(f); paper cop ements for Pa	y of Seque Itent Applic	nce Lis	ting; copy of Containing
Sequen	ce and/or Amino A	Acid Sequen	ce Disclosures and	d return postcar	<u>d</u> .				
	Small entity sta submitted.	atus of this	application unde	r 37 CFR § 1.	27 ha	as been estat	lished by	verified	d statement
	A verified stater	ment to esta	blish small entity s	tatus under 37	CFR §	§§ 1.9 and 1.2	7 is enclose	ed.	
	Petition for a	month	extension of time.						
\boxtimes	No additional fe	e is required	i .						
	The fee has bee	en calculate	d as shown below:						
	1110 100 1100 000	J. 100.00.00.00.00.00.00.00.00.00.00.00.00.	2 40 0//0////						Othe
					_	Small	Entity	\neg	Sma
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra		Rate	Add'I Fee	or	Rate
Total		Minus			7	x \$9=			x \$18=
Indep.		Minus				x 42=			x \$84=
	esentation of Multip	ple Dep. Cla	nim			+\$140=			+ \$280=
	,					Total add'l fee	\$		Tota add'l fee
	Please charge I copy of this she		ount No. 23-1925 ed.	(BRINKS HOF	ER GI	LSON & LION	E) in the a	mount	of \$ /
	A check in the a	amount of \$_	to cover the	filing fee is end	losed				
\boxtimes	any patent app	plication pro	y authorized to ch ocessing fees un count No. 23-1925	der 37 CFR §	1.17	7 associated	with this		
\boxtimes		any associa	CFR § 1.136(a) f ted fees which ha						
				Respectfu	lly sul	omitted,			
				Gregory M Registration	n Ne	1, Ph.D. 48,492	jal 1	<u> </u>	
P.O. BO CHICAG	S HOFER GILSON DX 10395 GO, ILLINOIS 6061 21-4200			Agent IOLA	,ppiic	will			

FEB 1 1 2002 B

Our Case No. 10466/264

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Ashkenazi et al.)
Serial No. 09/989,293) Examiner To be assigned)
Filing Date: November 20, 2001) Group Art Unit No. 1645
For SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODY G THE SAME))

STATEMENT ACCORDING TO 37 C.F.R. § 1.821(f)

BOX SEQUENCE LISTING

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:


Submitted herewith is a copy of the sequence listing in paper and computer readable form. Applicants' representative states that the content of the attached paper copy and compact disc copy in computer readable form of the Sequence Listing, submitted in accordance with 37 CFR 1.821(c) and (e), respectively, are identical.

Respectfully submitted,

Gregory M. Zinkl, Ph.D. Registration No. 48,492 Agent for Applicant

BRINKS HOFER GILSON & LIONE P.O. BOX 10395 CHICAGO, ILLINOIS 60610 (312) 321-4200

BEST AVAILABLE COPY



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
WWW.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/989,293

11/20/2001

Avi J. Ashkenazi

P2730P1C66

CONFIRMATION NO. 9393

FORMALITIES LETTER

OC000000007274229

Paul E. Rauch, Ph.D. Brinks, Hofer, Gilson & Lione NBC Tower - Suite 3600 455 N. Cityfront Plaza Drive Chicago, IL 60611-5599

Date Mailed: 01/07/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE